Posted by Michael Wonder on 26 Apr 2023
Sales agent change gives red light to Gavreto’s reimbursement review
26 April 2023 - The changes in sales right for Gavreto (pralsetinib), an RET inhibitor, may likely negatively influence the on-going review for its insurance benefits, drawing the industry’s attention.
Roche recently discontinued its cooperation contract with Blueprint Medicines, the developer of Gavreto. Accordingly, Roche Korea will be responsible for its sales only until the end of this year.
